2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Atkins M, Jegede O, Haas N, Mcdermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Einstein D, Catalano P, Hammers H, Regan M. Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal For ImmunoTherapy Of Cancer 2024, 12: e008293. PMID: 38604810, PMCID: PMC11015345, DOI: 10.1136/jitc-2023-008293.Peer-Reviewed Original ResearchConceptsTreatment-free survivalInternational Metastatic RCC Database ConsortiumFavorable-risk patientsNivolumab monotherapyPhase II study of nivolumabCessation of immunotherapyFavorable-risk diseaseProtocol therapy cessationStudy of nivolumabSystemic therapy initiationTreatment naive patientsPhase II studyRenal cell carcinomaKaplan-Meier curvesActive treatment approachPartitioned survival analysisCheckMate 067Stable diseaseProtocol therapyAdvanced melanomaTherapy initiationTreatment-freeCell carcinomaClear-cellProtocol treatment
2014
Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303
Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303. Clinical Cancer Research 2014, 20: 5041-5051. PMID: 25107914, PMCID: PMC4184913, DOI: 10.1158/1078-0432.ccr-14-0051.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCetuximabCisplatinDisease ProgressionFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingRadiotherapyRisk FactorsSquamous Cell Carcinoma of Head and NeckTreatment OutcomeConceptsProgression-free survivalOverall survivalLA-SCCHNMaintenance cetuximabAdvanced squamous cell headMedian progression-free survivalTwo-year overall survivalNeck squamous cell carcinomaTumor human papillomavirus (HPV) statusGrade 5 toxicityMedian overall survivalMedian radiotherapy doseMost common gradeCycles of cisplatinHuman papillomavirus (HPV) statusPhase II studySquamous cell headTumor HPV statusLonger overall survivalSquamous cell carcinomaOropharyngeal primaryHPV statusII studyPrimary endpointProtocol treatment
2008
Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840—Cancer and Leukemia Group B
Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840—Cancer and Leukemia Group B. Journal Of Clinical Oncology 2008, 26: 2659-2665. PMID: 18509177, PMCID: PMC4830463, DOI: 10.1200/jco.2007.13.9782.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerHazard of deathTreatment failureBreast cancerOverall survivalClinical outcomesLeukemia Group B trialAfrican AmericansLeukemia Group BMedian overall survivalTreatment-related toxicityObserved survival differencesTime of presentationAfrican American patientsRacial differencesOverall responseAfrican American womenLarge cooperative groupsMetastatic settingProtocol treatmentPrognostic factorsStudy cohortSubsequent therapyShorter survivalPooled analysis
2007
264: Preliminary Cost Estimation of Goal-Directed Protocol Treatment of Sepsis: What is the Role of the ED in Generating Costs Relative to Total Hospital Costs?
Venkatesh A, Schmidt M, Carney M, Bhayani R, Courtney D. 264: Preliminary Cost Estimation of Goal-Directed Protocol Treatment of Sepsis: What is the Role of the ED in Generating Costs Relative to Total Hospital Costs? Annals Of Emergency Medicine 2007, 50: s83. DOI: 10.1016/j.annemergmed.2007.06.250.Peer-Reviewed Original Research
2003
RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy
Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2003, 57: 665-672. PMID: 14529770, DOI: 10.1016/s0360-3016(03)00718-1.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellChemotherapy, AdjuvantCisplatinCombined Modality TherapyConfidence IntervalsCystectomyFemaleHumansMaleMethotrexateMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingRadiation-Sensitizing AgentsRadiotherapyRemission InductionUrinary Bladder NeoplasmsVinblastineConceptsGrade 3 toxicityAdjuvant chemotherapyInduction therapyOverall survivalResidual diseaseAdditional adjuvant chemotherapyBladder-sparing treatmentCycles of methotrexateGrade 4 hydronephrosisGrade 4 neutropeniaSelective bladder conservationEvidence of diseaseClinical T stagePositive cytologic findingsAggressive transurethral resectionRTOG 97Surgery specimenKarnofsky scoreLocoregional controlLocoregional failureCombination cisplatinMost patientsPathologic reviewProtocol treatmentVinblastine chemotherapy
1986
Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Winkler C, Sausville E, Ihde D, Fischmann A, Schechter G, Kumar P, Nibhanupdi J, Minna J, Makuch R, Eddy J. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. Journal Of Clinical Oncology 1986, 4: 1094-100. PMID: 3088220, DOI: 10.1200/jco.1986.4.7.1094.Peer-Reviewed Original ResearchConceptsTotal skin electron beam irradiationStage I patientsCutaneous T-cell lymphomaDisease-free survivalT-cell lymphomaI patientsStage IIComplete responseModality treatmentCell lymphomaStage IMedian disease-free survivalDisease-free survivorsThree-drug regimensCombined modality treatmentAdvanced-stage patientsOverall response rateOral corticosteroidsAdvanced diseaseSystemic chemotherapyProtocol treatmentTopical therapyStage patientsCR rateSimultaneous chemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply